Ichiro Tsuboi

Sep 12, 2024 | nature.com | Akihiro Matsukawa |Takafumi Yanagisawa |Marcin Miszczyk |Ichiro Tsuboi |Ekaterina Laukhtina |Juan Rivas | +4 more

AbstractRecent advancements in the management of biochemical recurrence (BCR) following local treatment for prostate cancer (PCa), including the use of androgen receptor signaling inhibitors (ARSIs), have broadened the spectrum of therapeutic options. We aimed to compare salvage therapies in patients with BCR after definitive local treatment for clinically non-metastatic PCa with curative intent.